SANA Sana Biotechnology, Inc.

Nasdaq sana.com


$ 5.92 $ 1.47 (33.03 %)    

Wednesday, 15-Oct-2025 19:53:46 EDT
QQQ $ 602.61 $ 4.22 (0.71 %)
DIA $ 463.04 $ 0.00 (0 %)
SPY $ 665.11 $ 2.94 (0.44 %)
TLT $ 90.76 $ -0.20 (-0.22 %)
GLD $ 387.41 $ 6.60 (1.73 %)
$ 5.92
$ 4.51
$ 5.77 x 200
$ 6.20 x 50
-- - --
$ 1.26 - $ 7.30
36,027,560
na
1.41B
$ 1.91
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-11-2025 06-30-2025 10-Q
2 05-08-2025 03-31-2025 10-Q
3 03-17-2025 12-31-2024 10-K
4 11-08-2024 09-30-2024 10-Q
5 08-08-2024 06-30-2024 10-Q
6 05-08-2024 03-31-2024 10-Q
7 02-29-2024 12-31-2023 10-K
8 11-08-2023 09-30-2023 10-Q
9 08-03-2023 06-30-2023 10-Q
10 05-08-2023 03-31-2023 10-Q
11 03-16-2023 12-31-2022 10-K
12 11-02-2022 09-30-2022 10-Q
13 08-04-2022 06-30-2022 10-Q
14 05-10-2022 03-31-2022 10-Q
15 03-16-2022 12-31-2021 10-K
16 11-08-2021 09-30-2021 10-Q
17 08-04-2021 06-30-2021 10-Q
18 05-05-2021 03-31-2021 10-Q
19 03-24-2021 12-31-2020 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 sana-biotech-stock--the-next-100-bagger

Sana Biotech stock soars after outspoken stock promoter Eric Jackson names it as his latest potential "100-bagger."

 wedbush-initiates-coverage-on-sana-biotechnology-with-outperform-rating-announces-price-target-of-5

Wedbush analyst Martin Fan initiates coverage on Sana Biotechnology (NASDAQ:SANA) with a Outperform rating and announces Pr...

 sana-biotechnology-q2-adj-eps-016-beats-021-estimate

Sana Biotechnology (NASDAQ:SANA) reported quarterly losses of $(0.16) per share which beat the analyst consensus estimate of $(...

 update-sana-biotechnology-launches-75m-public-offering-of-common-stock-and-pre-funded-warrants

Sana Biotechnology, Inc. (NASDAQ:SANA) ("Sana"), a company focused on changing the possible for patients through engine...

 sana-biotechnology-study-published-in-nejm-shows-hip-modified-islet-cells-function-without-immunosuppression-in-type-1-diabetes-patient

Data Demonstrate that Sana's Hypoimmune (HIP)-Modified Pancreatic Islet Cells, Transplanted with No Immunosuppression, Pers...

 how-to-trade-this-150-gainer-chasing-a-cure-for-type-1-diabetes

An update on Sana Biotechnology.

 morgan-stanley-assumes-sana-biotechnology-at-overweight-announces-price-target-of-12

Morgan Stanley analyst Maxwell Skor assumes Sana Biotechnology (NASDAQ:SANA) with a Overweight rating and announces Price Ta...

 jmp-securities-reiterates-market-outperform-on-sana-biotechnology-maintains-5-price-target

JMP Securities analyst Reni Benjamin reiterates Sana Biotechnology (NASDAQ:SANA) with a Market Outperform and maintains $5 p...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION